Highlights the critical need for research focused on understanding the pathophysiological mechanisms and optimal treatments for acute myocardial infarction in patients over 75 years old.
Evidence gaps in AMI for patients >75 urge clinical caution; leaves open optimal treatments until dedicated trials clarify mechanisms.
The short- and long-term mortality of patients greater than 75 years of age with acute myocardial infarction is still very high. These patients have been excluded from most randomized controlled trials designed to test interventions directed to improve the outcome of acute myocardial infarction. Contrary to young-old patients (65-74 years) in whom the benefit obtained with these interventions is even greater than that observed in younger patients, there is a lack of information concerning the optimal treatment of acute myocardial infarction in the oldest patients. Research specifically directed to assess the optimal reperfusion strategy and coadjuvant therapies in patients greater than 75 years old is critically important. The causes for such high mortality are still poorly understood. Several clinical observations suggest that old patients with acute myocardial infarction have specific pathophysiologic behaviors. As the knowledge of the mechanisms of disease is, in clinical practice, the basis of therapy development, clinical and basic research designed to elucidate the specific pathophysiological mechanisms and causes of the high mortality in the oldest patients with acute myocardial infarction should be regarded as a priority in geriatric cardiovascular research.
No takes yet. Share an insight, caveat, or question.
Héctor Bueno (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: